Atazanavir News and Research

RSS
Atazanavir, also known as Reyataz, is a type of medicine called a protease inhibitor (PI). PIs block protease, a protein that HIV needs to make more copies of itself. Atazanavir was approved by the FDA on June 20, 2003, for use with other antiretroviral medication in the treatment of HIV infection. This medicine does
not cure or prevent HIV infection or AIDS and
does not reduce the risk of passing the virus to
other people.
FDA approves new treatment for all HCV genotypes 1-6

FDA approves new treatment for all HCV genotypes 1-6

FDA approves new combo drug Mavyret for adults with Hepatitis C infection

FDA approves new combo drug Mavyret for adults with Hepatitis C infection

ARV drug atazanavir may have significant effects on infant development

ARV drug atazanavir may have significant effects on infant development

MPP signs licensing agreement with AbbVie to address future demands for HIV treatment in Africa

MPP signs licensing agreement with AbbVie to address future demands for HIV treatment in Africa

MPP collaborates with University of Liverpool to accelerate development of HIV nanomedicines

MPP collaborates with University of Liverpool to accelerate development of HIV nanomedicines

Results from phase 3 women-only HIV study show improved safety, efficacy of Stribild drug

Results from phase 3 women-only HIV study show improved safety, efficacy of Stribild drug

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

MPP announces 7 new sub-licensing agreements for manufacture of generic HIV medicines

MPP announces 7 new sub-licensing agreements for manufacture of generic HIV medicines

FSC Laboratories acquires exclusive marketing rights for Aciphex Sprinkle in the U.S.

FSC Laboratories acquires exclusive marketing rights for Aciphex Sprinkle in the U.S.

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck's NOXAFIL injection gets FDA approval for intravenous use

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Amneal launches generic Esomeprazole strontium delayed-release capsules 49.3 mg

Amneal launches generic Esomeprazole strontium delayed-release capsules 49.3 mg

Amneal's Esomeprazole Strontium 49.3 mg delayed-release capsules now available for GERD patients

Amneal's Esomeprazole Strontium 49.3 mg delayed-release capsules now available for GERD patients

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck announces approval of NOXAFIL delayed-release tablets by FDA

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Children exposed to HIV in womb are no more likely to show language delays

Children exposed to HIV in womb are no more likely to show language delays